RSS

Chiasma

Capsugel has announced an agreement with Chiasma, Inc., wherein Capsugel’s dosage form solutions (DFS) business unit is scaling up manufacturing for what is claimed to be the only investigational oral form of octreotide in clinical development. more

Technology